NVIDIA entered a collaboration with Simulations Plus to apply GPU acceleration and AI-assisted workflows to drug development and quantitative systems pharmacology (the study of how drugs move through and affect the body).
The partnership targets complex modeling and simulation tasks in early-stage drug discovery, with GPU-optimized workflows for physiologically based pharmacokinetics and quantitative systems pharmacology potentially cutting end-to-end modeling times by up to 75% in testing.
NVIDIA extends its life sciences presence through this specialist software provider, whose tools are already used in pharmaceutical R&D, while the move complements existing partnerships with IREN and Corning on AI infrastructure.
Ask the AI about this article →
For example, today's edition would include:
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · takes 30 seconds · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. Q&As are published on this page for other readers too.
Israeli startup DataAgent Ltd
Taoyuan is positioning itself as a northern hub for AI data centers (AIDC), citing the Tatan area and an LNG c…
SK Hynix presented a custom HBM concept at SEMICON Taiwan 2026, where compute functions are placed in the base…
The U.S. Department of Defense announced on August 31 that it has deployed ChatGPT Mil, a customized version o…
Nvidia reported earnings that were both remarkable and boring, reflecting its focus on avoiding a consolidated…
Anthropic has agreed to a $35bn cloud-computing contract with Lambda, a Nvidia-backed cloud provider
